Recursion

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company that integrates large-scale experimental biology and chemistry with advanced computational infrastructure. The company aims to enhance the efficiency of drug discovery and development by decoding biology, integrating automation, algorithms, and data-driven methods toward this goal.

Recursion’s headquarters is in Salt Lake City, where it is a founding member of the Utah life sciences collective BioHive. The company also has offices in Montreal, New York, London, and Oxford. Its workforce of approximately 600 employees is balanced between life sciences experts and computational and technical professionals. The governance structure clearly distinguishes between the executive team and the board of directors.

Recursion OS

Recursion OS is an internal platform that encompasses the entire drug R&D pipeline, from target identification to clinical trials. The platform generates and continuously updates a purpose-built data corpus from multi-layered inputs including phenotyping, transcriptomic, proteomic, ADME outputs, and de-identified patient data from partners. This structure is supported by the weekly execution of millions of wet-lab experiments and the conversion of their outputs into digital representations. Machine learning and foundational models trained on this platform generate a searchable map of trillions of relationships between biology and chemistry.

LOWE is a workflow engine integrated with Recursion OS that enables scientists to access tools via a natural language interface. It orchestrates multi-step tasks such as relationship mapping on the map, target-drug interaction querying with MatchMaker, compound design using generative chemistry, synthesis, and experimental planning. The system aims to reduce time and resource consumption in early discovery phases through ADMET calculations, commercial compound sourcing, and visualization support.

On the wet-lab side, the company conducts high-volume experiment generation through standardized, automation-driven workflows. On the computational side, it operates advanced hardware infrastructure, including the BioHive-2 supercomputer built in partnership with NVIDIA. This capacity enables industrial-scale execution of data processing, model training, and large-scale search tasks.

Partnerships

Recursion employs diverse partnership models with pharmaceutical companies and technology providers, ranging from discovery platform access to asset development. These collaborations span multiple disease areas including oncology, neuroscience, immunology, and fibrosis. When known chemical assets from third parties are identified as having new potential applications on the Recursion Map, licensing and in-house development options are evaluated.

Corporate Approach

Recursion embraces the industrialization of drug discovery as its core principle. By combining standardization with precise execution, the establishment of data connectivity and model-experiment cycles aims to accelerate the path from hypothesis to validation. The company’s internal values are defined around integrity, time-sensitive execution, direct communication, accountability, effective learning, and cross-functional collaboration.